The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors
Authors:
- Melisa GurbuzMGMelisa Gurbuz
- Cagla TekinCTCagla Tekin
- Melis ErcelikMEMelis Ercelik
- Sevin Avsar KocSKSevin Avsar Koc
- Feray KockarFKFeray Kockar
- Pınar EserPEPınar Eser
- Mevlut Ozgur TaskapiliogluMTMevlut Ozgur Taskapilioglu
- Gulcin TezcanGulcin Tezcan
- Burcu ErbaykentBEBurcu Erbaykent
- Ahmet BekarABAhmet Bekar
- Hasan KocaeliHKHasan Kocaeli
- Mine OzsenMOMine Ozsen
Open Access
- 31 March 2026
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 177 (2)
Abstract
Background: Atypical teratoid/rhabdoid tumors (AT/RT) are aggressive pediatric CNS malignancies characterized by SMARCB1 loss, which leads to the dysregulated expression of Enhancer of Zeste Homolog 2 (EZH2), a key catalytic component of the Polycomb Repressive Complex 2 (PRC2). This dysregulation results in aberrant trimethylation of histone H3 at lysine 27 (H3K27me3), driving tumor progression. While EZH2 inhibitors like tazemetostat are in clinical use, their efficacy remains limited, necessitating a deeper understanding of PRC2 regulation. We investigated the role of long non-coding RNAs (lncRNAs) in modulating the EZH2-PRC2 axis in AT/RT. Methods: Expression levels of lncRNAs (MALAT1, ANRIL, KCNQ1OT1) were analyzed via RT-PCR in 10 archival AT/RT patient tissues. RNA immunoprecipitation (RIP) was performed to identify direct interactions with EZH2. The functional impact of MALAT1 inhibition on H3K27me3 levels, mesenchymal markers (CDH2, TWIST, ZEB1), and tumorigenic behaviors (migration, invasion, sphere formation) was evaluated in vitro. Results: MALAT1, ANRIL, and KCNQ1OT1 were significantly overexpressed in AT/RT tissues ( p < 0.05). RIP assays revealed that only MALAT1 directly interacts with EZH2 in DAOY and primary AT/RT cells. MALAT1 knockdown significantly reduced H3K27me3 levels ( p < 0.05) and markedly impaired cell migration, invasion, and sphere-forming capacity. These phenotypic changes were associated with the downregulation of key mesenchymal markers (CDH2, TWIST, ZEB1). Conclusions: Our findings identify MALAT1 as a critical epigenetic regulator in AT/RT that interacts with EZH2 to maintain the PRC2-mediated repressive landscape. Targeting the MALAT1-EZH2 axis provides a novel translational perspective to enhance the efficacy of epigenetic therapies in AT/RT.Keywords
Funding Information
- Bursa Uludağ University
This publication has 33 references indexed in Scilit:
- Elevated Bromide Levels Due to Tazemetostat Therapy Treated With Salt and Water Supplementation in Two Children With Atypical Teratoid Rhabdoid TumorPediatric Blood & Cancer, 2025
- Polycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistanceFunctional & Integrative Genomics, 2025
- Recent progress and novel approaches to treating atypical teratoid rhabdoid tumorNeoplasia, 2023
- EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospectsBiomedicine & Pharmacotherapy, 2022
- Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient casesActa Neuropathologica, 2020
- Translational genomics of malignant rhabdoid tumours: Current impact and future possibilitiesSeminars in Cancer Biology, 2020
- Molecular Mechanisms Directing PRC2 Recruitment and H3K27 MethylationMolecular Cell, 2019
- Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene RegulationCancer Cell, 2019
- Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing ProgramPediatric Blood & Cancer, 2016
- Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targetsChild's Nervous System, 2009